39341-83-8 Usage
Description
HLH, also known as Luteinizing Hormone (LH), is a gonadotropic glycoprotein hormone secreted from the anterior pituitary. It plays a crucial role in the reproductive system of both males and females. In females, LH triggers ovulation and stimulates the development of the corpus luteum, while in males, it stimulates androgen production and spermatogenesis.
Uses
Used in Fertility Treatments:
HLH is used as a treatment for female infertility, particularly in cases where there is a need to stimulate the production of estrogens and the transformation of ovarian follicles into corpora lutea. Recombinant human LH is employed for this purpose.
Used in Infertility Treatments for Women:
HLH, in the form of menotropins (human menopausal gonadotropin, hMG), which is a mixture of FSH and LH, is used to treat infertility in women. This combination helps stimulate the development of ovarian follicles and the production of estrogens.
Used as an LH Substitute:
HLH, derived from the urine of pregnant women in the form of hCG (human chorionic gonadotropin), is used as an LH substitute. It serves the same purpose as LH in the reproductive system, particularly in stimulating the production of estrogens and the development of the corpus luteum in females.
Used in Predicting Ovulation:
A surge in LH levels is tested to predict ovulation using urinary ovulation predictor kits. This helps in identifying the most fertile days in a woman's menstrual cycle, which can be useful for family planning or infertility treatments.
Used in Drug Delivery Systems:
While not explicitly mentioned in the provided materials, it can be inferred that HLH agonists and antagonists, such as hCG and purified or recombinant human LH, may be used in drug delivery systems to enhance the efficacy of fertility treatments. These agonists and antagonists can be incorporated into various formulations to improve the delivery, bioavailability, and therapeutic outcomes of LH-based treatments.
Structure
LH is a glycoprotein consisting of noncovalently
linked glycoprotein hormone (GPH) α- and LH
β-subunits. The GPH α-subunit is common to folliclestimulating hormone (FSH), thyroid-stimulating
hormone (TSH), and chorionic gonadotropin (CG). The LH β-subunit
contains a cysteine-knot motif, which is critical for the
heterodimer assembly and biological activity of the hormone. The N-linked oligosaccharide chain is important
for the intracellular folding, secretion, metabolic clearance, and biological activity of the hormone.?Mr 26,000–48,000. pI: human LH, 7.2–9.2; rat LH, 8.6–9.3;
pig LH, 7.2–9.2; horse LH, 4.5–7.5. Multiple isoforms exist
due to the microheterogeneity of oligosaccharide chains.
Soluble in water; insoluble in alcohol and acetone. Partially
(50%) dissociated to two subunits at pH 1.9. Inactivated by
oxidation (hydrogen peroxide, periodic acid), reduction
(cysteine, ketone), and treatment with trypsin, chymotrypsin, and pepsin. Picrolonic, flavianic, picric, and trichloroacetic acids precipitate LH with retention of its activity.
Gene, mRNA, and precursor
The human LH β-subunit gene, LHB, location 2p21,
consists of three exons. The human LH
β-subunit mRNA has 523 b that encode a signal peptide
of 20 aa residues and a mature protein of 121 aa residues.?The LH β-subunit gene is expressed in the basophilic
gonadotropes in the anterior pituitary. In tetrapods,
FSH and LH are coexpressed in gonadotropes, whereas
they are produced in different cells in teleosts.
Receptors
The receptor of LH (LHR) is a glycoprotein that
belongs to a subclass of the rhodopsin/β-adrenergic subfamily of the membrane-bound GPCR superfamily. The
LHR consists of around 700 aa residues and contains a
large N-terminal extracellular domain (~360 aa residues),
seven transmembrane domains, and a C-terminal intracellular domain.??The receptor mainly couples to the Gs protein, and LH
stimulates the production of cAMP in target cells.
Clinical implications
A single mutation (Gly 578 Asp) in the sixth transmembrane domain of LHR resulting in the constitutive
activation of the LHR causes familial male precocious
puberty.16 A missense mutation (Ala 593 Pro) in the
sixth transmembrane domain of LHR causes Leydig cell
hypoplasia. Conditions with high LH levels include
premature menopause, gonadal dysgenesis, Turner
syndrome, castration, Swyer syndrome, polycystic
ovary syndrome, certain forms of congenital adrenal
hyperplasia, testicular failure, and pregnancy. Conditions with low FSH levels include Kallmann syndrome,
hypothalamic suppression, hypopituitarism, eating disorders, female athlete triad, hyperprolactinemia, and
hypogonadism.
Synthesis and release
The synthesis and release of LH are regulated by GnRH,
gonadotropin-inhibitory hormone (GnIH), gonadal steroids, and dopamine. In tetrapods, GnRH acts directly
on gonadotropes and differentially regulates LH and
FSH secretion through changes in the pattern of GnRH
pulsatile secretion. GnIH inhibits LH secretion in birds
and mammals, whereas GnIH can stimulate and inhibit
LH secretion in fish depending on the species and reproductive status. LH secretion is regulated by gonadal steroids such as estradiol and testosterone. Gonadal
steroids exert their effects at the level of the hypothalamus
by changing GnRH secretion, and directly at the level of
the gonadotropes, where they exert different effects
depending on the species and reproductive condition of
animals. In teleosts, dopamine inhibits both basal and
GnRH-stimulated LH secretion.
Check Digit Verification of cas no
The CAS Registry Mumber 39341-83-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,9,3,4 and 1 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 39341-83:
(7*3)+(6*9)+(5*3)+(4*4)+(3*1)+(2*8)+(1*3)=128
128 % 10 = 8
So 39341-83-8 is a valid CAS Registry Number.